Brazilian guidelines for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children

Read full text
Authors: Arnaldo Lopes Colombo, Marcello Mihailenko Chaves Magri, Fabianne Altruda de Moraes Costa Carlesse, Diego R. Falci, Marcia Maiolino Garnica, Daniel Wagner de Castro Lima Santos, Flávio Queiroz‐Telles, Alessandro Comarú Pasqualotto
Cited by: 1
References: 344

Abstract

BACKGROUND: Invasive candidiasis, including candidemia and deep-seated Candida infections, remains a major cause of morbidity and mortality in hospitalized patients worldwide, particularly in low- and middle-income countries. In Brazil, candidemia is associated with persistently high mortality rates, driven by late diagnosis, limited access to antifungal agents, and heterogeneous diagnostic capacity. The last national guideline issued by the Brazilian Society of Infectious Diseases (SBI) was published in 2013, and substantial advances have occurred since then in epidemiology, diagnostics, and antifungal therapy. OBJECTIVES: To provide an updated, evidence-based Brazilian guideline for the diagnosis and treatment of candidemia and invasive candidiasis in adults and children, incorporating contemporary scientific data and addressing the specific epidemiological, diagnostic, and therapeutic realities of Brazil. METHODS: This guideline was developed by the SBI Mycology Committee through a structured consensus process. Clinical questions were formulated using the PICO framework, followed by systematic literature searches of PubMed-indexed studies and international guidelines. Recommendations were contextualized according to Brazilian epidemiology, laboratory infrastructure, and access to antifungal therapies. RESULTS: Key updates include revised epidemiological data from Brazilian cohorts, updated recommendations for blood culture strategies and non-culture-based diagnostics, refined indications for echocardiography and fundoscopy, and updated therapeutic algorithms. Novel antifungal agents, including long acting echinocandins such as rezafungin, are discussed. Emphasis is placed on early echinocandin therapy, timely source control, antifungal stewardship, and infectious diseases consultation. CONCLUSIONS: This updated Brazilian guideline reflects current scientific evidence while addressing national healthcare realities, aiming to standardize care, improve outcomes, and reduce mortality associated with invasive candidiasis in Brazil.

Fields of Study & Subjects

Animal Law and Welfare Immunodeficiency and Autoimmune Disorders Leprosy Research and Treatment

Publication details

Journal / source
The Brazilian Journal of Infectious Diseases
Publisher
Elsevier BV
Volume
30
Issue
4
Pages
105946–105946
Publication date
1 July 2026
Language
EN